Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis

Clinical Cancer Research

Volumn 22, Issue 22, 2016, Pages 5574-5581

  Yamamura, Kensuke ^a   Baba, Yoshifumi ^a   Nakagawa, Shigeki ^a   Mima, Kosuke ^a   Miyake, Keisuke ^a   Nakamura, Kenichi ^a   Sawayama, Hiroshi ^a   Kinoshita, Koichi ^a   Ishimoto, Takatsugu ^a   Iwatsuki, Masaaki ^a   Sakamoto, Yasuo ^a   Yamashita, Yoichi ^a   Yoshida, Naoya ^a   Watanabe, Masayuki ^b   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CYTOKINE; CYTOKINE RECEPTOR; GENOMIC DNA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; TUMOR MARKER; CHEMOKINE;

AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; FEMALE; FUNCTIONAL STATUS; FUSOBACTERIUM NUCLEATUM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MICROBIOME; NONHUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SEX; SURVIVAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TOBACCO USE; TUMOR LOCALIZATION; ESOPHAGUS TUMOR; GENETICS; METABOLISM; MICROBIOLOGY; MICROFLORA; PATHOLOGY; PROGNOSIS;

AGED; CHEMOKINES; DNA, BACTERIAL; ESOPHAGEAL NEOPLASMS; FEMALE; FUSOBACTERIUM NUCLEATUM; HUMANS; MALE; MICROBIOTA; PROGNOSIS;

EID: 84995923686     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1786     Document Type: Article

References (50)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349: 2241-52.
2. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007;25:4110-7.
3. Brucher BL, Swisher SG, Konigsrainer A, Zieker D, Hartmann J, Stein H, et al. Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol 2009;16:878-86.
4. Wouters MW, Karim-Kos HE, le Cessie S, Wijnhoven BP, Stassen LP, Steup WH, et al. Centralization of esophageal cancer surgery: does it improve clinical outcome? Ann Surg Oncol 2009;16: 1789-98.
5. Arthur JC, Gharaibeh RZ, Muhlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun 2014; 5:4724.
6. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014;12:661-72.
7. Garrett WS. Cancer and the microbiota. Science 2015;348:80-6.
8. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-3.
9. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, et al. Differential adaptation of human gut microbiota to bariatric surgeryinduced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010;59:3049-57.
10. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003;52: 79-83.
11. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;146: 1489-99.
12. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-7.
13. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012;3:279-88.
14. Yoneda M, Naka S, Nakano K, Wada K, Endo H, Mawatari H, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol 2012;12:16.
15. Furusho H, Miyauchi M, Hyogo H, Inubushi T, Ao M, Ouhara K, et al. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice. J Gastroenterol 2013;48: 1259-70.
16. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012;13:260-70.
17. Griffen AL, Beall CJ, Campbell JH, Firestone ND, Kumar PS, Yang ZK, et al. Distinct and complex bacterial profiles in human periodontitis and health revealed by 16S pyrosequencing. Isme j 2012;6:1176-85.
18. Han YW. Fusobacterium nucleatum: a commensal-turned pathogen. Curr Opin Microbiol 2015;23:141-7.
19. Tahara T, Shibata T, Kawamura T, Okubo M, Ichikawa Y, Sumi K, et al. Fusobacterium detected in colonic biopsy and clinicopathological features of ulcerative colitis in Japan. Dig Dis Sci 2015;60:205-10.
20. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012;22:299-306.
21. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292-8.
22. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 2013; 14:195-206.
23. Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 2014;33:1381-90.
24. Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2015 Aug 26. [Epub ahead of print].
25. Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 2015;137: 1258-68.
26. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010; 17:1721-4.
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
28. Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol 2015;1:653-61.
29. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
30. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15: 1016-22.
31. Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338:120-3.
32. Abreu MT, Peek RM Jr. Gastrointestinal malignancy and the microbiome. Gastroenterology 2014;146:1534-46.
33. Mitsuhashi K, Nosho K, Sukawa Y, Matsunaga Y, Ito M, Kurihara H, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 2015;6: 7209-20.
34. Han YW, Ikegami A, Rajanna C, Kawsar HI, Zhou Y, Li M, et al. Identification and characterization of a novel adhesin unique to oral fusobacteria. J Bacteriol 2005;187:5330-40.
35. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207-15.
36. Verbeke H, Geboes K, Van Damme J, Struyf S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta 2012;1825:117-29.
37. Tachezy M, Zander H, Gebauer F, von Loga K, Pantel K, Izbicki JR, et al. CXCR7 expression in esophageal cancer. J Transl Med 2013; 11:238.
38. Lukaszewicz-Zajac M, Mroczko B, Kozlowski M, Szmitkowski M. The serum concentrations of chemokine CXCL12 and its specific receptor CXCR4 in patients with esophageal cancer. Dis Markers 2016;2016: 7963895.
39. Ogura M, Takeuchi H, Kawakubo H, Nishi T, Fukuda K, Nakamura R, et al. Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma. Surgery 2013;154:512-20.
40. Kretschmer I, Freudenberger T, Twarock S, Yamaguchi Y, Grandoch M, Fischer JW. Esophageal squamous cell carcinoma cells modulate chemokine expression and hyaluronan synthesis in fibroblasts. J Biol Chem 2016;291:4091-106.
41. Nandi B, Pai C, Huang Q, Prabhala RH, Munshi NC, Gold JS. CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis. PLoS One 2014;9:e97566.
42. Vicinus B, Rubie C, Stegmaier N, Frick VO, Kolsch K, Kauffels A, et al. miR- 21 and its target gene CCL20 are both highly overexpressed in the microenvironment of colorectal tumors: significance of their regulation. Oncol Rep 2013;30:1285-92.
43. Wang GZ, Cheng X, Li XC, Liu YQ, Wang XQ, Shi X, et al. Tobacco smoke induces production of chemokine CCL20 to promote lung cancer. Cancer Lett 2015;363:60-70.
44. Campbell AS, Albo D, Kimsey TF, White SL, Wang TN. Macrophage inflammatory protein-3alpha promotes pancreatic cancer cell invasion. J Surg Res 2005;123:96-101.
45. Wang B, Shi L, Sun X, Wang L, Wang X, Chen C. Production of CCL20 from lung cancer cells induces the cell migration and proliferation through PI3K pathway. J Cell Mol Med 2016;20:920-9.
46. Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, Pappu B, et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 2008;181:8391-401.
47. Cook KW, Letley DP, Ingram RJ, Staples E, Skjoldmose H, Atherton JC, et al. CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa. Gut 2014;63:1550-9.
48. Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 2011;6:e24671.
49. Suzuki H, Onishi H, Morisaki T, Tanaka M, Katano M. Intratumoral FOXP3+VEGFR2+ regulatory T cells are predictive markers for recurrence and survival in patients with colorectal cancer. Clin Immunol 2013;146: 26-33.
50. Liu JY, Li F, Wang LP, Chen XF, Wang D, Cao L, et al. CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. Br J Cancer 2015;113:747-55.